AR105848A1 - Derivados heterocíclicos antibacterianos - Google Patents
Derivados heterocíclicos antibacterianosInfo
- Publication number
- AR105848A1 AR105848A1 ARP160102629A ARP160102629A AR105848A1 AR 105848 A1 AR105848 A1 AR 105848A1 AR P160102629 A ARP160102629 A AR P160102629A AR P160102629 A ARP160102629 A AR P160102629A AR 105848 A1 AR105848 A1 AR 105848A1
- Authority
- AR
- Argentina
- Prior art keywords
- 4alkyl
- cycloprop
- phosphonooxy
- carbonyloxymethyl
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) donde: V representa O ó S; R² y R³ representan, de manera independiente, hidrógeno o flúor; y M es uno de los grupos de fórmula (2) y (3), donde en el grupo de fórmula (2): A representa un enlace o -CºC-; R¹A representa hidrógeno, o halógeno; R²A representa hidrógeno, o halógeno; y R³A representa C₁₋₃alcoxi; hidroxi-C₁₋₄alquilo; o RNA¹RNA²N-C₁₋₃alquilo, donde RNA¹ y RNA² representan, de manera independiente, hidrógeno o C₁₋₃alquilo; o RNA¹ y RNA² junto con el nitrógeno al cual están unidos forman un anillo saturado de 4 a 6 miembros que opcionalmente contiene un átomo de anillo de oxígeno, donde dicho anillo está no sustituido, o monosustituido con flúor; y donde en el grupo de fórmula (3): R¹B representa hidroxi-C₁₋₄alquilo; 1-(3-hidroxiazetidina)-1-carboniloximetilo; 1-hidroximetil-cicloprop-1-ilo, o un grupo que es uno de sus profármacos, donde dicho grupo es 1-((fosfonooxi)metilo)-cicloprop-1-ilo, 1-[(di(C₁₋₄alquiloamino)-C₁₋₃alquilo-carboniloximetil]-cicloprop-1-ilo, 1-{[(2-(fosfonooxi-C₁₋₄alquilo)-fenilo)-C₁₋₄alquilo]-carboniloximetil}-cicloprop-1-ilo, 1-{[2-(fosfonooxi-C₁₋₄alquilo)-fenilo]-carboniloximetil}-cicloprop-1-ilo, o 1-{[(2-fosfonooxi-fenilo)-C₁₋₄alquilo]-carboniloximetil}-cicloprop-1-ilo; trans-2-hidroximetil-cicloprop-1-ilo, o un grupo que es uno de sus profármacos donde dicho grupo es trans-2-(fosfonooximetilo)-cicloprop-1-ilo, trans-2-[(diC₁₋₄alquiloamino)-C₁₋₃alquilo-carboniloximetil]-cicloprop-1-ilo, trans-2-{[(2-(fosfonooxi-C₁₋₄alquilo)-fenilo)-C₁₋₄alquilo]-carboniloximetil}-cicloprop-1-ilo, trans-2-{[2-(fosfonooxi-C₁₋₄alquilo)-fenilo]-carboniloximetil}-cicloprop-1-ilo, o trans-2-{[(2-fosfonooxi-fenilo)-C₁₋₄alquilo]-carboniloximetil}-cicloprop-1-ilo; 2-flúor-2-hidroximetil-cicloprop-1-ilo, o un grupo que es uno de sus profármacos, donde dicho grupo es 2-flúor-2-(fosfonooximetilo)-cicloprop-1-ilo, 2-flúor-2-[(diC₁₋₄alquiloamino)-C₁₋₃alquilo-carboniloximetil]-cicloprop-1-ilo, 2-flúor-2-{[(2-(fosfonooxi-C₁₋₄alquilo)-fenilo)-C₁₋₄alquilo]-carboniloximetil}-cicloprop-1-ilo, 2-flúor-2-{[2-(fosfonooxi-C₁₋₄alquilo)-fenilo]-carboniloximetil}-cicloprop-1-ilo, o 2-flúor-2-{[(2-fosfonooxi-fenilo)-C₁₋₄alquilo]-carboniloximetil}-cicloprop-1-ilo; 3-hidroxi-oxetan-3-ilo; trans-2-(1,2-dihidroxietilo)cicloprop-1-ilo; trans-(cis-3,4-dihidroxi)-ciclopent-1-ilo; RNB¹RNB²N-C₁₋₃alquilo, donde RNB¹ y RNB² representan, de manera independiente, hidrógeno o C₁₋₃alquilo; 1-(RNB³RNB⁴N)-cicloprop-1-ilo, donde RNB³ y RNB⁴ representan, de manera independiente, hidrógeno o C₁₋₃alquilo, o RNB³ representa hidrógeno y RNB⁴, (fosfonooxi)metoxi-carbonilo; azetidin-3-ilo, donde dicho azetidin-3-ilo está no sustituido, o mono- o di-sustituido, donde, si se presenta, un sustituyente se une en la posición 1 de dicho grupo azetidin-3-ilo, donde dicho sustituyente es seleccionado de C₁₋₃alquilo, C₃₋₄cicloalquilo, oxetan-3-ilo, w-flúor-C₂alquilo, o w-hidroxi-C₂₋₄alquilo; y/o un sustituyente es flúor unido en la posición 3 de dicho grupo azetidin-3-ilo; R¹ representa hidrógeno, o R¹ representa -PO₃H₂, -SO₃H, fosfonooximetilo, o el grupo L representado por la fórmula (4), donde R⁴ representa C₁₋₄alquiloaminoC₁₋₄alquilo, diC₁₋₄alquiloaminoC₁₋₄alquilo, fosfonooxiC₁₋₄alquilo, fosfonooximetoxi, 2-(fosfonooxi-C₁₋₄alquilo)-fenilo, [2-(fosfonooxi-C₁₋₄alquilo)-fenilo]-C₁₋₄alquilo, o (2-(fosfonooxi)-fenilo)-C₁₋₄alquilo; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2015069837 | 2015-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105848A1 true AR105848A1 (es) | 2017-11-15 |
Family
ID=56893949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160102629A AR105848A1 (es) | 2015-08-31 | 2016-08-29 | Derivados heterocíclicos antibacterianos |
Country Status (10)
Country | Link |
---|---|
US (1) | US20180251434A1 (es) |
EP (1) | EP3344609A1 (es) |
JP (1) | JP2018527349A (es) |
KR (1) | KR20180043355A (es) |
CN (1) | CN107922361A (es) |
AR (1) | AR105848A1 (es) |
CA (1) | CA2989968A1 (es) |
MA (1) | MA43883A (es) |
TW (1) | TW201718529A (es) |
WO (1) | WO2017037039A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
AR105646A1 (es) | 2015-08-11 | 2017-10-25 | Actelion Pharmaceuticals Ltd | Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida |
AR105889A1 (es) | 2015-09-03 | 2017-11-22 | Actelion Pharmaceuticals Ltd | Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103717582B (zh) * | 2011-04-08 | 2015-09-30 | 辉瑞大药厂 | 用作抗菌剂的异*唑衍生物 |
MX2013011432A (es) * | 2011-04-08 | 2013-12-09 | Pfizer | Derivados de imidazol, pirazol, y triazol utiles como agentes antibacterianos. |
AR097617A1 (es) * | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
US9624206B2 (en) * | 2013-12-19 | 2017-04-18 | Actelion Pharmaceuticals Ltd | Antibacterial 1H-indazole and 1H-indole derivatives |
AR099612A1 (es) * | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
BR112017010474A2 (pt) * | 2014-11-19 | 2017-12-26 | Actelion Pharmaceuticals Ltd | derivados antibacterianos de benzotiazol |
-
2016
- 2016-08-29 AR ARP160102629A patent/AR105848A1/es unknown
- 2016-08-30 MA MA043883A patent/MA43883A/fr unknown
- 2016-08-30 KR KR1020187008546A patent/KR20180043355A/ko unknown
- 2016-08-30 US US15/755,411 patent/US20180251434A1/en not_active Abandoned
- 2016-08-30 TW TW105127785A patent/TW201718529A/zh unknown
- 2016-08-30 EP EP16763225.6A patent/EP3344609A1/en not_active Withdrawn
- 2016-08-30 JP JP2018511154A patent/JP2018527349A/ja active Pending
- 2016-08-30 WO PCT/EP2016/070362 patent/WO2017037039A1/en active Application Filing
- 2016-08-30 CA CA2989968A patent/CA2989968A1/en not_active Abandoned
- 2016-08-30 CN CN201680048834.7A patent/CN107922361A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
MA43883A (fr) | 2018-12-05 |
JP2018527349A (ja) | 2018-09-20 |
EP3344609A1 (en) | 2018-07-11 |
CN107922361A (zh) | 2018-04-17 |
US20180251434A1 (en) | 2018-09-06 |
CA2989968A1 (en) | 2017-03-09 |
WO2017037039A1 (en) | 2017-03-09 |
KR20180043355A (ko) | 2018-04-27 |
TW201718529A (zh) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109349A1 (es) | Compuestos y usos | |
BR112017006253A2 (pt) | novos compostos | |
CO2017002714A2 (es) | Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo | |
PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
CR20150661A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas | |
CL2020002423A1 (es) | Nuevos compuestos heterocíclicos | |
EA201591503A1 (ru) | Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина | |
CU20200051A7 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
AR100251A1 (es) | Inhibidores de la dematilasa-1 especifica de lisina | |
CY1119423T1 (el) | Παραγωγο κυκλοαλκυλ-υποκατεστημενης ιμιδαζολης | |
RS54730B1 (sr) | Inhibitori beta sekretaze | |
AR094712A1 (es) | Modificador de sabor dulce | |
AR094978A1 (es) | Derivados de pirazol agonistas de receptores canabinoides | |
AR115662A2 (es) | Derivados de piperidina | |
AR106604A1 (es) | Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico | |
AR100428A1 (es) | Derivados antibacterianos quinazolina-4(3h)-ona | |
AR105848A1 (es) | Derivados heterocíclicos antibacterianos | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
MA40302B1 (fr) | Dérivés de carbazole | |
AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
DK2197860T3 (da) | Nye forbindelser som adenosin-A1-receptorantagonister | |
AR090086A1 (es) | COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b | |
AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
AR101222A1 (es) | Derivados de piridona | |
MA50093B1 (fr) | Composé pentacyclique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |